Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Natco Pharma launches...

    Natco Pharma launches Valsartan Sacubitril tablets in India under brand name VALSAC

    Farhat NasimWritten by Farhat Nasim Published On 2019-01-31T10:30:07+05:30  |  Updated On 31 Jan 2019 10:30 AM IST
    Natco Pharma launches Valsartan Sacubitril tablets in India under brand name VALSAC

    Valsartan Sacubitril is a combination drug used for certain types of heart failure and works by relaxing blood vessels, making it easier for the heart to pump blood to the body.


    Hyderabad: Soon after diversifying its portfolio by entering into agrichemical space, the Hyderabad based Natco Pharma Limited has announced the launch of Valsartan-Sacubitril tablet, under its brand VALSAC.


    NATCO has launched VALSAC in 50 mg & 100 mg strengths at an MRP of INR 45.0 and INR 55.0, per tablet, respectively.


    Valsartan-Sacubitril is a combination drug used for certain types of heart failure and works by relaxing blood vessels, making it easier for the heart to pump blood to the body.


    Valsartan belongs to a class of drugs called angiotensin receptor blockers (ARBs). It works by relaxing blood vessels so that blood can flow more easily. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. While Sacubitril is an antihypertensive drug used in combination with valsartan.


    Also Read:EU cracks down on Valsartan- blood pressure medicine made by Mylan


    The firm has recently diversified its portfolio by entering into agrichemical space and initiated work on it green-field manufacturing facilities for producing niche products in that area in Nellore District of Andhra Pradesh. The facility will manufacture both agrichemical technical and formulation products. Natco expects the facilities to be commissioned by the end of 2019 with a total capital expenditure of Rs 100 crore.


    Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of Rs 3.3 million. The firm has seven manufacturing facilities spread across India with modern research laboratories. It is involved in developing, manufacturing and marketing finished dosage formulations (FDF) and active pharmaceutical ingredients (APIs).



    Medical Dialogues had earlier reported about the company's recent foray into the agrichemical space.


    Also Read: Natco Pharma ventures into agrichemical space set up Rs 100 crore facility in AP
    blood vesselscombo drugdrug launch in indiaformulation productsHeart failure drugHyderabad pharmaNatco pharmapharma news in indiaPharmaceuticalsVALSACValsartan SacubitrilValsartan+Sacubitril

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok